npj Parkinson s DiseaseNeurosciencePeer-reviewed journal article
Emergent glutamate & dopamine dysfunction in VPS35(D620N) knock-in mice and rapid reversal by LRRK2 inhibition
Anusha KameshiD, Chelsie KadgieniD, Naila KuhlmanniD, S. Coady, Andrea PietrantonioiD, Yuting Cousineau, Anouar KhayachiiD, Agostinho SantosiD, Emily P. HurleyiD, Jessica C. BarroniD, Matthew P. ParsonsiD, Austen J. MilnerwoodiD
Abstract
The D620N variant in Vacuolar Protein Sorting 35 (VPS35) causes autosomal-dominant, late- onset Parkinsons disease. VPS35 is a core subunit of the retromer complex that canonically recycles transmembrane cargo from sorting endosomes. Although retromer cargoes include many synaptic proteins, VPS35s neuronal functions are poorly understood. To investigate the consequences of the Parkinsons mutation, striatal neurotransmission was assessed in 1-, 3- & 6-month-old VPS35 D620N knock-in (VKI) mice. Spontaneous and optogenetically- evoked corticostriatal glutamate transmission was increased in VKI striatal spiny projection neurons by 6 months, when total striatal glutamate release, quantified by iGluSnFR imaging, showed similarities to wild-type. dLight imaging revealed robust increases in VKI striatal dopamine release by 6 months, which were reversed with acute ex vivo leucine-rich repeat kinase 2 (LRRK2) inhibition. We conclude that increased glutamate and dopamine transmission in VKI mice progressively emerges in young-adulthood, and that dopamine dysfunction is likely the result of sustained, rapidly-reversible, LRRK2 hyperactivity.
- Citations
- 1
- FWCI
- 0.61
- Field percentile
- top 36%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Inhibition of LRRK2 kinase activity rescues deficits in striatal dopamine dynamics in VPS35 p.D620N knock-in mice
Mengfei Bu, Jordan Follett, … Matthew James Farrer·bioRxiv·May 14, 2023
- Surface GluA1 and glutamate transmission are increased in VPS35 D620N neurons and altered by LRRK2 kinase inhibition
Chelsie Kadgien, Anusha Kamesh, … Austen J. Milnerwood·Molecular BrainPeer-reviewed·Sep 16, 2021
- Vps35 p.D620N causes Lrrk2 kinase hyperactivity, chronic microglial activation and inflammation
Isaac Bul Deng, Mengfei Bu, … Matthew James Farrer·bioRxiv·Sep 3, 2026
- The Parkinson's Disease related mutant VPS35 (D620N) amplifies the LRRK2 response to endolysosomal stress
K. R. McCarron, H. Elcocks, … M. J. Clague·bioRxiv·Dec 2, 2023
- VPS35 and α-Synuclein Fail to Interact to Modulate Neurodegeneration in Rodent Models of Parkinson's Disease
Xi Chen, Elpida Tsika, … Darren J. Moore·Molecular NeurodegenerationPeer-reviewed·Aug 4, 2023
- Sex- and age-dependent control of dopamine function by LRRK2, and rapid reversal of dopamine release deficits in the LRRK2-G2019S knock-in mouse model of Parkinson's Disease.
Christina Gentle, Anusha Kamesh, … Austen J. Milnerwood·bioRxiv·Oct 16, 2026